Latest Forum Topics /
EFH Ltd
Last:0.049
-0.002
|
 Post Reply
|
|
BIO PHARMA company do research on MEDICAL DISEASES
|
|||
|
ST3-trading
Senior |
05-Mar-2021 09:24
|
||
|
x 0
x 0 Alert Admin |
is this stock totally dead one . ? siao liao | ||
| Useful To Me Not Useful To Me | |||
|
StevenLow
Member |
02-Mar-2021 16:04
|
||
|
x 0
x 0 Alert Admin |
I told management to advised Jeremy to do share buyback.. | ||
| Useful To Me Not Useful To Me | |||
|
|
|||
|
des_khor
Supreme |
02-Mar-2021 15:58
Yells: "Tell me who is God or Market Fortune Teller in this forum ??" |
||
|
x 0
x 0 Alert Admin |
So low ?
|
||
| Useful To Me Not Useful To Me | |||
|
StevenLow
Member |
02-Mar-2021 15:51
|
||
|
x 0
x 0 Alert Admin |
I am getting out of sgx and into US stocks.. Already joined Tiger Traders..commission at $1.99usd..sgx is $2.99sgd.. | ||
| Useful To Me Not Useful To Me | |||
|
Starship
Supreme |
02-Mar-2021 15:48
|
||
|
x 0
x 0 Alert Admin |
They thinking must wait till 10c.  
|
||
| Useful To Me Not Useful To Me | |||
|
|
|||
|
newbieliu
Elite |
02-Mar-2021 15:48
|
||
|
x 0
x 0 Alert Admin |
Old comrades.. thansk our biolidics is sinking again sad....
|
||
| Useful To Me Not Useful To Me | |||
|
StevenLow
Member |
02-Mar-2021 15:45
|
||
|
x 0
x 0 Alert Admin |
I already called Biolidics management to inform them that their shares is dropping to $0.20..what happens? | ||
| Useful To Me Not Useful To Me | |||
|
ST3-trading
Senior |
01-Mar-2021 21:54
|
||
|
x 0
x 0 Alert Admin |
Why JEREMY prove us wrong . ? | ||
| Useful To Me Not Useful To Me | |||
|
|
|||
|
WBdisciple
Elite |
01-Mar-2021 08:13
|
||
|
x 0
x 0 Alert Admin |
https://www.investor-one.com/editorial/12851-Analyzing-a-Precision-Medical-Technology-Company-using-4-Financial-Metrics With a stronger trailing 12-month financial performance, Biolidics has managed to reduce its losses as compared to the past financial years. Coupled with the high liquidity ratio, this further highlights the strength in its balance sheet. However, investors will have to take notice of its negative free cash flow across the years. In the press release dated 26th February 2021, Biolidics has achieved a record revenue of S$8.91 million as the sale of COVID-19 Antibody Test Kits was the key contributor to the Group&rsquo s revenue growth in FY2020. In terms of prospects, on the infectious diseases front, Biolidics aims to provide testing applications for the entire range of infection stages for COVID-19 and the following are the recent key milestones: In November 2020, Biolidics entered into a distribution agreement with JOYSBIO (Tianjin) Biotechnology Co, Ltd for the SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold) (the &ldquo JOYSBIO Antigen Rapid Test Kit&rdquo ). The JOYSBIO Antigen Rapid Test Kit has received the provisional authorisation from Singapore&rsquo s Health Sciences Authority. In January 2021, Biolidics launched the ClearEpi SARS-CoV-2 Antigen Rapid Test Kit (the &ldquo ClearEpi ART&rdquo ), and this test kit has received confirmation for the CE marking. The CE marking indicates that the ClearEpi ART complies with the relevant EU safety, health and environmental protection requirements which enables the ClearEpi ART to be marketed in the EU. In the area of cancer diagnostics, Biolidics has established various partnerships in Asia, for the development and commercialisation of a wide range of clinical or laboratory developed tests (&ldquo LDTs&rdquo ) using the Company' s ClearCell® FX1 system and CTChip® FR1 biochip. |
||
| Useful To Me Not Useful To Me | |||
|
Sgvale
Supreme |
01-Mar-2021 07:45
|
||
|
x 0
x 0 Alert Admin |
No worry. You own nothing just spectator
|
||
| Useful To Me Not Useful To Me | |||
|
Stockguru2020
Member |
01-Mar-2021 04:10
|
||
|
x 0
x 0 Alert Admin |
Wa Lau eh useless counter. Tomorrow confirm sell down jialat jialat. Cannot make money shit counter. Die liao sure get burn tomorrow | ||
| Useful To Me Not Useful To Me | |||
|
humbleman
Senior |
27-Feb-2021 21:55
|
||
|
x 0
x 0 Alert Admin |
i think this almost certainly is a sell call. COVID 19 such a boost and STILL cannot make money | ||
| Useful To Me Not Useful To Me | |||
|
|
|||
|
gregtan123
Supreme |
27-Feb-2021 21:09
|
||
|
x 0
x 0 Alert Admin |
All swap to the Parent of Bio which is Clearbridge, that one make $$$ liao | ||
| Useful To Me Not Useful To Me | |||
|
Sgvale
Supreme |
27-Feb-2021 20:38
|
||
|
x 0
x 0 Alert Admin |
So many tie up & collaboration. If no profit generated , then all activities are wasted effort.
Not doing anything probably is better. |
||
| Useful To Me Not Useful To Me | |||
|
Starship
Supreme |
27-Feb-2021 18:43
|
||
|
x 0
x 0 Alert Admin |
" Overall, the Group recorded a loss of S$4.65 million in FY2020 as compared to S$4.81 million in FY2019."
|
||
| Useful To Me Not Useful To Me | |||
|
Starship
Supreme |
27-Feb-2021 18:41
|
||
|
x 0
x 0 Alert Admin |
Never-ending hype abt it' s new tie-ups, new brands, new collaborations, new licenses etc throughout 2020, yet managed to chalk up only a teeny weeny $8m revenue?  Is this a Circus or what? Really No Eyes See...........................  
|
||
| Useful To Me Not Useful To Me | |||
|
Sgvale
Supreme |
27-Feb-2021 18:09
|
||
|
x 0
x 0 Alert Admin |
No profit ? | ||
| Useful To Me Not Useful To Me | |||
|
Joelton
Supreme |
27-Feb-2021 13:54
|
||
|
x 0
x 0 Alert Admin |
Biolidics&rsquo Revenue Surges 519.4% to a Record of S$8.91 Million in FY2020
&bull The sale of COVID-19 Antibody Test Kits was the key contributor to the Group&rsquo s revenue growth in FY2020
&bull Balance sheet further strengthened with total assets at S$18.76 million and cash and cash equivalents increased to S$10.67 million as at 31 December 2020
&bull The Group aims to expand its portfolio of COVID-19 test kits to provide testing applications for the entire range of infection stages for COVID-19
Singapore, 26 February 2021 &ndash Biolidics Limited (&ldquo Biolidics&rdquo or the &ldquo Company&rdquo and together with its subsidiaries, the &ldquo Group&rdquo ), a medical technology company with a focus on innovative diagnostic solutions, has announced today its unaudited results for the financial year ended 31 December 2020 (&ldquo FY2020&rdquo ).
The Group&rsquo s revenue for FY2020 surged by 519.4% to S$8.91 million from S$1.44 million in the financial year ended 31 December 2019 (&ldquo FY2019&rdquo ), which was driven mainly by the sale of its test kits for the detection of the Novel Coronavirus 2019 antibodies (the &ldquo COVID-19 Antibody Test Kits&rdquo ) that contributed S$7.81 million in FY2020. In addition, the Group&rsquo s sales of its ClearCell® FX1 system, CTChip® FR1 biochip and other related services and consumables contributed S$1.06 million in FY2020 as compared to S$1.17 million in FY2019.
Overall, the Group recorded a loss of S$4.65 million in FY2020 as compared to S$4.81 million in FY2019. Excluding the one-off expense for professional fees of S$0.40 million, equity- settled share-based payments of S$1.95 million and income from government grants of S$0.52 million, the Group would have recorded a lower loss for FY2020 of S$2.82 million.
As at 31 December 2020, the Group&rsquo s total assets increased to S$18.76 million, with cash and cash equivalents increasing to S$10.67 million.
|
||
| Useful To Me Not Useful To Me | |||
|
WBdisciple
Elite |
18-Feb-2021 19:39
|
||
|
x 0
x 0 Alert Admin |
Chinese cancer screening firm triples in Hong Kong IPO debut [HONG KONG] Chinese cancer screening biotech firm New Horizon Health more than tripled on its Hong Kong debut on Thursday, notching the biggest first-day rise in the city' s history for initial public offerings (IPO) raising at least HK$2 billion (S$342.5 million). New Horizon Health closed at HK$84, up 215 per cent from the offer price of HK$26.66, which was already at the upper end of a marketed range. The biotech company raised US$263 million in the IPO. Thursday' s pop shows that the IPO frenzy that' s gripped Hong Kong is intact, coming two weeks after short-video company Kuaishou Technology leaped 161 per cent in its debut, the second-best ever for an IPO over US$1 billion in the world. Over one million Hong Kong investors put in orders worth some HK$844 billion for Qiming Venture Partners-backed New Horizon Health' s IPO. That represents a subscription rate of 4,133 times, the second-highest on record after Most Kwai Chung' s 2018 IPO, according to data compiled by Bloomberg. First-time share sales have had their best start to the year on record in Asia, helped by Kuaishou' s mammoth offering and fuelled by markets awash with liquidity, a stock rally, as well as hordes of retail investors bidding for shares. The dizzying first-day pops as well as the flurry of IPOs by blank-cheque companies in the US have led some to warn of overheated markets. |
||
| Useful To Me Not Useful To Me | |||
|
Bigdaddy
Veteran |
18-Feb-2021 19:31
|
||
|
x 0
x 0 Alert Admin |
llast min jump up to 33. tomorrow will test 35 and then 38! good ride fro now |
||
| Useful To Me Not Useful To Me | |||